Bisiayo Fashemi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bisiayo Fashemi has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Dineo Khabele
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA
67 shared publications - Andrea R. Hagemann
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, Alvin J. Siteman Cancer Center, St. Louis, Missouri
65 shared publications - Carolyn K. McCourt
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine in St Louis, St Louis, Missouri
65 shared publications - Lindsay M. Kuroki
Washington University School of Medicine in St. Louis, Obstetrics and Gynecology, St. Louis, MO, US
65 shared publications - Mary M. Mullen
Washington University School of Medicine in St. Louis
65 shared publications - Alba Llop-Guevara
Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
64 shared publications
Latest Publications
- Open Access
Single-cell transcriptomics of heterogeneous patient-derived organoids reveals novel therapeutic targets in high-grade serous ovarian cancer
High-grade serous ovarian carcinoma (HGSOC) is characterized by widespread peritoneal dissemination and poor long-term survival, largely driven by metastatic relapse following initial response to chemotherapy. Defining the molecular programs that enable tumor progression from the primary ovarian site to metastatic niches remains a key challenge. Here, we leverage patient-derived organoids (PDOs) coupled with single-cell RNA sequencing (scRNA-seq) to interrogate tumor evolution and identify regulators of metastatic competence in HGSOC. We profiled PDOs and matched formalin-fixed paraffin-embedded (FFPE) tumor samples from ovarian and omental disease sites across seven patients. Single-cell transcriptomic analysis revealed conserved and patient-specific cellular states and enabled reconstruction of inferred trajectories of tumor progression. Comparative trajectory analysis identified gene expression programs associated with metastatic transition from ovarian to omental tumors. Among these, the heparan sulfate proteoglycan AGRIN emerged as a consistently upregulated gene along the metastatic axis. Cell-cell communication analyses suggested that AGRIN -mediated signaling involves both epithelial tumor cells and stromal components, implicating the extracellular matrix in shaping metastatic behavior through mechanotransduction and integrin-associated pathways. Functional validation using genetic depletion of AGRIN in ovarian cancer cell lines demonstrated reduced migratory and invasive capacity, supporting a causal role for AGRIN in promoting metastatic phenotypes. Together, these findings identify AGRIN as a regulator of metastatic competence in HGSOC and highlight extracellular matrix–associated signaling as a key driver of disease progression. More broadly, this study demonstrates that PDO-based single-cell transcriptomic approaches can uncover actionable regulators of metastasis and provide a scalable framework for therapeutic target discovery across cancer types. Significance: Patient-derived organoids analyzed by single-cell transcriptomics reveal dynamic tumor evolution and uncover AGRIN as a regulator of metastatic competence in HGSOC, demonstrating the utility of living tumor models for therapeutic target discovery.
Open AccessSingle-cell transcriptomics of heterogeneous patient-derived organoids reveals novel therapeutic targets in high-grade serous ovarian cancer
High-grade serous ovarian carcinoma (HGSOC) is characterized by widespread peritoneal dissemination and poor long-term survival, largely driven by metastatic relapse following initial response to chemotherapy. Defining the molecular programs that enable tumor progression from the primary ovarian site to metastatic niches remains a key challenge. Here, we leverage patient-derived organoids (PDOs) coupled with single-cell RNA sequencing (scRNA-seq) to interrogate tumor evolution and identify regulators of metastatic competence in HGSOC. We profiled PDOs and matched formalin-fixed paraffin-embedded (FFPE) tumor samples from ovarian and omental disease sites across seven patients. Single-cell transcriptomic analysis revealed conserved and patient-specific cellular states and enabled reconstruction of inferred trajectories of tumor progression. Comparative trajectory analysis identified gene expression programs associated with metastatic transition from ovarian to omental tumors. Among these, the heparan sulfate proteoglycan AGRIN emerged as a consistently upregulated gene along the metastatic axis. Cell-cell communication analyses suggested that AGRIN -mediated signaling involves both epithelial tumor cells and stromal components, implicating the extracellular matrix in shaping metastatic behavior through mechanotransduction and integrin-associated pathways. Functional validation using genetic depletion of AGRIN in ovarian cancer cell lines demonstrated reduced migratory and invasive capacity, supporting a causal role for AGRIN in promoting metastatic phenotypes. Together, these findings identify AGRIN as a regulator of metastatic competence in HGSOC and highlight extracellular matrix–associated signaling as a key driver of disease progression. More broadly, this study demonstrates that PDO-based single-cell transcriptomic approaches can uncover actionable regulators of metastasis and provide a scalable framework for therapeutic target discovery across cancer types. Significance: Patient-derived organoids analyzed by single-cell transcriptomics reveal dynamic tumor evolution and uncover AGRIN as a regulator of metastatic competence in HGSOC, demonstrating the utility of living tumor models for therapeutic target discovery.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 expression and platinum chemotherapy response in vitro and in patient tumors
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 expression and platinum chemotherapy response in vitro and in patient tumors
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Flow diagram of HGSOC patient-derived samples used for RAD51 foci assay
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Flow diagram of HGSOC patient-derived samples used for RAD51 foci assay
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 scores in BRCA mutated tumors shows correlation with survival and protein integrity
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 scores in BRCA mutated tumors shows correlation with survival and protein integrity
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of FFPE validation cohort
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of FFPE validation cohort
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer organoids
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer organoids
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
γH2AX score in established and patient-derived ovarian cancer cell lines and patient-derived organoids
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
γH2AX score in established and patient-derived ovarian cancer cell lines and patient-derived organoids
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer cells
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer cells
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of FFPE discovery cohort
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of FFPE discovery cohort